Mavacamten in Real-Life Practice: Initial Experience at a Hypertrophic Cardiomyopathy Centre
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.14882 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Zaid Abood und 10 weiteren Autor:innen. Beteiligte Einrichtung: Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Stroke Volume, Ventricular Function, Left, Ventricular Outflow Obstruction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Colton Scholarship.
Abstract (Originalsprache)
Aims
In clinical trials, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). We aimed to share our real-world experience with the efficacy and safety of mavacamten in this patient population. Methods and results This retrospective, single-centre study included patients with symptomatic oHCM from March 2023 to November 2023. Inclusion criteria were oHCM, age >18 years, significant LVOTO (gradient >50 mmHg at rest or with Valsalva), New York Heart Association (NYHA) class ≥II despite maximally tolerated medical therapy, and left ventricular ejection fraction (LVEF) >55%. Patients were evaluated by echocardiography, NYHA class, electrocardiography and Holter monitor on each monthly visit for 3 months. A total of 31 patients were included in this study. The mean (SD) age was 58 (16.5) years, and 14 (45%) were female. Mean provoked left ventricular outflow tract gradient (LVOTG) reduced by −49.4 mmHg (P < 0.001) at 4 weeks, −59.2 mmHg (P < 0.001) at 8 weeks, and −60.8 mmHg (P < 0.001) at 12 weeks. Twenty-six of the 31 patients (83.8%) achieved an LVOTG ≤30 mmHg at Week 12. No major side effects were reported. Sixty-seven percent experienced ≥2 NYHA class improvements, LVEF remained above 55% and no dose titration was made.
Conclusions
Our real-world experience aligns with established mavacamten trial outcomes. Continuous vigilance and longitudinal investigations are needed to further assess potential long-term impacts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.
- Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA.
- Academic Affairs, Cardiovascular Research, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.
Förderung
- Colton Scholarship
Zitieren
APA
Abood, Z., Jan, M. F., Ashraf, M., Kroboth, S., Sanders, H., Schweitzer, M., Misicka, A., Ollerman, E., Jahangir, A., Galazka, P., & Tajik, A. J. (2025). Mavacamten in Real-Life Practice: Initial Experience at a Hypertrophic Cardiomyopathy Centre. ESC Heart Failure. https://doi.org/10.1002/ehf2.14882
Vancouver
Abood Z, Jan MF, Ashraf M, Kroboth S, Sanders H, Schweitzer M, et al. Mavacamten in Real-Life Practice: Initial Experience at a Hypertrophic Cardiomyopathy Centre. ESC Heart Failure. 2025. doi:10.1002/ehf2.14882
BibTeX
@article{Abood2025,
author = {Abood, Zaid and Jan, Muhammad Fuad and Ashraf, Muddasir and Kroboth, Stacie and Sanders, Heather and Schweitzer, McKenzie and Misicka, Amanda and Ollerman, Emily and Jahangir, Arshad and Galazka, Patrycja and Tajik, Abdul Jamil},
title = {Mavacamten in Real-Life Practice: Initial Experience at a Hypertrophic Cardiomyopathy Centre},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.14882}
}
EUVIMED